Marcela Maus
#114,322
Most Influential Person Now
American immunologist
Marcela Maus's AcademicInfluence.com Rankings
Marcela Mausbiology Degrees
Biology
#10970
World Rank
#14336
Historical Rank
#2534
USA Rank
Immunology
#882
World Rank
#905
Historical Rank
#98
USA Rank
Download Badge
Biology
Marcela Maus's Degrees
- Doctorate Medicine University of Buenos Aires
- PhD Immunology University of Buenos Aires
Why Is Marcela Maus Influential?
(Suggest an Edit or Addition)According to Wikipedia, Marcela V. Maus is an associate professor of medicine at Harvard Medical School and director of the Cellular Immunotherapy Program at Massachusetts General Hospital. She works on immunotherapy for the treatment of cancer, using genetically engineered T cells to target malignancies .
Marcela Maus's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. (2018) (1270)
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma (2017) (1047)
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (2013) (896)
- Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma (2019) (840)
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies (2013) (665)
- CD8+ T-cell responses to adeno-associated virus capsid in humans (2007) (632)
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies. (2014) (576)
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. (2015) (487)
- Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB (2002) (443)
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma (2015) (382)
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans (2013) (371)
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. (2016) (359)
- Enhancing T cell therapy through TCR signaling-responsive nanoparticle drug delivery (2018) (354)
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. (2018) (324)
- Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing (2018) (319)
- Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells (2003) (302)
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity (2019) (279)
- Adoptive immunotherapy for cancer or viruses. (2014) (255)
- Ibrutinib treatment improves T cell number and function in CLL patients (2017) (244)
- Recent advances and discoveries in the mechanisms and functions of CAR T cells (2021) (242)
- Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy (2016) (217)
- Engineering and Design of Chimeric Antigen Receptors (2018) (212)
- Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies (2016) (208)
- 4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 (2007) (199)
- Chimeric antigen receptor T cell therapy: 25years in the making. (2016) (175)
- The Emerging Landscape of Immune Cell Therapies (2020) (170)
- Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. (2019) (169)
- Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. (2009) (162)
- Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance (2018) (150)
- Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. (2020) (149)
- Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment (2017) (148)
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma (2016) (145)
- Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma. (2019) (145)
- CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma (2019) (141)
- Making CAR T Cells a Solid Option for Solid Tumors (2018) (125)
- Gene editing for immune cell therapies (2019) (125)
- Prolactin as a chemoattractant for human breast carcinoma. (1999) (122)
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies (2020) (117)
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies (2020) (117)
- Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. (2018) (116)
- Engineered T cells for cancer therapy (2014) (106)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events (2020) (106)
- TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. (2003) (100)
- A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. (2002) (100)
- T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. (2013) (100)
- Biomanufacturing for clinically advanced cell therapies (2018) (97)
- Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response (2019) (94)
- Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. (2018) (91)
- Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide (2021) (87)
- Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. (2016) (80)
- Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy (2017) (77)
- Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity (2018) (77)
- Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. (2019) (76)
- HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. (2003) (73)
- Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. (2016) (72)
- CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells (2021) (71)
- Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2018) (69)
- An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity (2017) (68)
- PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial (2022) (67)
- Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs (2021) (66)
- Immunotherapy for Glioblastoma: Adoptive T-cell Strategies (2018) (64)
- bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study. (2018) (63)
- Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation (2002) (63)
- Immunotherapy for Brain Tumors. (2017) (62)
- Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. (2019) (60)
- Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
- State of the art in CAR T cell therapy for CD19+ B cell malignancies. (2020) (59)
- CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours (2022) (55)
- CAR-T Cell Therapies From the Transfusion Medicine Perspective. (2016) (53)
- First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results. (2017) (53)
- Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. (2017) (51)
- Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study (2020) (48)
- Inflammatory and Infectious Syndromes Associated with Cancer Immunotherapies. (2018) (45)
- Extensive Replicative Capacity of Human Central Memory T Cells1 (2004) (43)
- The Why, what, and How of the New FACT standards for immune effector cells (2017) (42)
- A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. (2020) (40)
- The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. (2017) (37)
- Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19 (2019) (37)
- Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. (2016) (35)
- Immunotherapy with chimeric antigen receptors for multiple myeloma. (2014) (34)
- CARs in the Lead Against Multiple Myeloma (2017) (34)
- Zoom Zoom: Racing CARs for Multiple Myeloma (2013) (31)
- Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology (2019) (30)
- Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma (2016) (30)
- SARS -CoV-2 T-cell immunity to variants of concern following vaccination (2021) (29)
- The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. (2020) (28)
- Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. (2019) (27)
- Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. (2022) (26)
- Emerging Immunotherapies for Malignant Glioma: From Immunogenomics to Cell Therapy. (2020) (26)
- BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. (2021) (25)
- Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. (2020) (23)
- Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers (2015) (23)
- T cells expressing a chimeric antigen receptor (2018) (23)
- CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies (2015) (23)
- Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) (2022) (22)
- Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma (2022) (22)
- Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons. (2018) (22)
- Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial. (2022) (21)
- Designing CAR T cells for glioblastoma (2015) (21)
- Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding (2019) (21)
- Chimeric antigen receptor-modified T cells strike back. (2016) (20)
- New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry (2020) (20)
- EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity. (2022) (19)
- Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells (2021) (19)
- Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. (2021) (18)
- Clinical Perspective: Treatment of Aggressive B-cell Lymphomas with FDA approved CAR-T cell therapies. (2020) (18)
- CARTs on the Road for Myeloma (2014) (18)
- CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity (2022) (18)
- Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (2022) (17)
- Detection of Echovirus 18 in Human Breast Milk (2008) (16)
- Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. (2020) (16)
- HIV-infected macrophages resist efficient NK cell-mediated killing while preserving inflammatory cytokine responses. (2021) (16)
- Mechanisms of response and resistance to CAR T cell therapies. (2021) (15)
- Toxicities associated with immunotherapies for hematologic malignancies. (2018) (15)
- Blockade or deletion of IFNg reduces macrophage activation without compromising CAR-T function in hematologic malignancies. (2021) (14)
- Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma (2021) (14)
- Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. (2015) (14)
- C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. (2020) (13)
- Anti-CD 19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma (2018) (13)
- Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma. (2017) (13)
- CAR-Based Approaches to Cutaneous T-Cell Lymphoma (2019) (13)
- TRANCE-and CD 40 Ligand-matured Dendritic Cells Reveal MHC Class I-restricted T Cells Specific for Autologous Tumor in Late-Stage Ovarian Cancer Patients 1 (2003) (12)
- Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. (2016) (11)
- Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity (2015) (11)
- Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study (2022) (11)
- Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma (2020) (10)
- IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA (2015) (10)
- Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays (2019) (10)
- Infections associated with the new 'nibs and mabs' and cellular therapies. (2020) (9)
- CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia (2021) (8)
- Immunology: T-cell tweaks to target tumours (2017) (8)
- Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer. (2019) (8)
- The future of engineered immune cell therapies (2022) (7)
- Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources (2020) (7)
- Engineering an Optimized Trimeric APRIL-Based CAR to Broaden Targetability of Multiple Myeloma (2018) (6)
- A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity (2021) (6)
- Evidence generation and reproducibility in cell and gene therapy research: A call to action (2021) (6)
- Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML) (2019) (6)
- Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism (2016) (6)
- UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. (2022) (6)
- CAR‐T cells beyond CD19, UnCAR‐Ted territory (2019) (5)
- Single-cell imaging of T cell immunotherapy responses in vivo (2021) (5)
- Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells. (2018) (5)
- Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. (2022) (4)
- Unraveling the Signaling Balance of Activation and Exhaustion of CAR T Cells. (2020) (4)
- Abstract LB-066: BiTE-armored CARs overcome antigen escape in EGFRvIII-targeted therapy for glioblastoma (2019) (4)
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma (2022) (4)
- Equity and diversity in academic medicine: a perspective from the JCI editors. (2019) (4)
- CD 19-Targeted CAR T Cells : A New Tool in the Fight against B Cell Malignancies (2015) (4)
- Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients (2022) (3)
- Case 35-2019: A 66-Year-Old Man with Pancytopenia and Rash. (2019) (3)
- 767 Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies (2020) (3)
- AAV-2 Capsid-Specific CD8+ T Cells Limit the Duration of Gene Therapy in Humans and Cross-React with AAV-8 Capsid. (2006) (3)
- Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte-X19 Products (2021) (3)
- A decade of CAR T cell evolution (2022) (3)
- Detection of CAR‐T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories (2021) (3)
- A Novel Phase-Change Hydrogel Substrate for T Cell Activation Promotes Increased Expansion of CD8+ Cells Expressing Central Memory and Naive Phenotype Markers (2016) (3)
- Four challenges to CAR T cells breaking the glass ceiling. (2022) (3)
- Publisher Correction: Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing (2020) (3)
- Closed loop bioreactor system for the ex vivo expansion of human T cells. (2019) (3)
- Tumour tamed by transfer of one T cell (2018) (2)
- The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. (2021) (2)
- Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies (2021) (2)
- Bispecific CAR T cells for multiple myeloma: natural ligand compared to tandem scFv design (2020) (2)
- Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma (2021) (2)
- Differential T cell immunity to SARS-CoV-2 in mRNA-1273 and BNT162b2 vaccinated individuals. (2022) (2)
- Latent human herpesvirus 6 is reactivated in chimeric antigen receptor T cells (2022) (2)
- Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma (2014) (2)
- Quantifying Capsid Peptide:MHC I Complexes Following Adeno-Associated Virus (AAV) Transduction (2007) (2)
- Abstract LB-083: Phase I study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma (2016) (2)
- Miniatures Mesothelin-Speci fi c Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies (2014) (2)
- Immunoengineering: Valet parking for CAR genes (2017) (1)
- Commentary: Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. (2021) (1)
- New CARs on and off the road: challenges and new developments in CAR-T cell therapy. (2021) (1)
- Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients (2021) (1)
- Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells (2019) (1)
- Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response (2019) (1)
- 730. T Cell Responses to AAV Vector Capsid in Normal Donors and Subjects Who Have Undergone Liver-Directed AAV-Mediated Gene Transfer (2006) (1)
- Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia (2022) (1)
- Abstract 4916: Development of a NGS-based method for EGFRvIII detection: sequence analysis of the junction (2015) (1)
- Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma. (2021) (1)
- malignancies Antibody-modified T cells: CARs take the front seat for hematologic (2014) (1)
- Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia (2022) (1)
- Innate immune signaling in CLL. (2016) (1)
- T Cell Responses to AAV Vector Capsid Limit the Duration of Transgene Expression in Humans after Liver-Directed Gene Therapy. (2005) (1)
- Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia (2021) (1)
- Chapter 19 – General Principles of Immunotherapy for Glioblastoma (2016) (1)
- Abstract B139: Toxicity testing of EGFRvIII CAR-based immunotherapy of glioblastoma: From bench to bedside (2016) (1)
- Series ANTIBODY DERIVATIVES AS NEW THERAPEUTICS FOR HEMATOLOGIC MALIGNANCIES Antibody-modi fi ed T cells : CARs take the front seat for hematologic malignancies (2014) (1)
- Author Correction: CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells (2021) (1)
- Tumour tamed by transfer of one T cell (2018) (0)
- Adoptive T‐Cell Transfer: Harnessing Immune Cells to Combat Disease (2015) (0)
- Significant Hypogammaglobulinemia in Patients Receiving CAR T-cell therapy (2021) (0)
- Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing (2019) (0)
- Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening (2022) (0)
- Consensus Grading for Cytokine Release Syndrome and Neurologic D 224 X X Toxicity Associated with Immune Effector Cells (2019) (0)
- A Cancer Drug Promotes Hair Growth (2014) (0)
- T cells in a (polymer) matrix (2015) (0)
- Effects of intermittent T-cell cluster disaggregation on proliferative capacity and checkpoint marker expression (2019) (0)
- Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors (2019) (0)
- Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel (2022) (0)
- Abstract B59: Enhancing T-cell therapy through TCR signaling-responsive nanogel drug delivery (2017) (0)
- Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells. (2018) (0)
- CLINICAL Cardiovascular toxicity and titin cross-reactivity of af fi nity-enhanced T cells in myeloma and melanoma (2013) (0)
- Abstract 569: Mesothelin CAR T cells secreting FAP specific T cell engaging molecule (TEAM) target pancreatic cancer and its tumor microenvironment (TME) (2022) (0)
- Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections (2022) (0)
- Abstract 3606: Lenalidomide switch control of CAR T-cell phenotype and function via degradable membrane-bound IL-7 (2022) (0)
- Abstract 3584: Characterization of a novel class of engineered (TCR) fusion constructs (TRuCTMs) aimed to treat solid tumors (2018) (0)
- Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma (2011) (0)
- 639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy (2022) (0)
- 221 CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors (2021) (0)
- Biology of human T cell activation (2003) (0)
- Loss of IFNgR1 signaling glioblastoma drives resistance to CAR T cell binding avidity and cytotoxicity due to lower downstream expression of ICAM-1 (2022) (0)
- Central Memory T Cells Extensive Replicative Capacity of Human (2004) (0)
- Linking the microbiome to CAR-T cell responses (2023) (0)
- The Long-Awaited Marriage of Cancer Genomics and Immunotherapy Bears Fruit (2014) (0)
- CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours (2022) (0)
- A Novel Splenocyte Approach for Characterizing T Cell Responses to Adeno-Associated Virus in the Normal Population: Implications on Gene Transfer. (2006) (0)
- Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). (2023) (0)
- Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer (2022) (0)
- Gene editing for immune cell therapies (2019) (0)
- Abstract 2330: Preclinical evaluation of TC-110: CD19-specific T cell receptor (TCR) fusion construct (TRuC™) T cell for the treatment of hematologic malignancies (2019) (0)
- Multiomics STEP up in correlative analysis of response to CAR T cells (2023) (0)
- Abstract IA19: New directions in T cell therapies for cancer (2018) (0)
- CAR T cells Contend with Myeloma in the Bone Marrow Microenvironment. (2022) (0)
- Nomenclature for Cellular and Genetic therapies: A Need for Standardization. (2022) (0)
- Intraventricular Delivery and CRISPR-Cas9 Disruption of PD-1 is Required for CAR T-cell Efficacy in Glioblastoma (2020) (0)
- Bispecific T-Cell Engager -Armored Chimeric Antigen Receptor T Cells Overcome Antigen Escape From EGFRvIII-Targeted Therapy For Glioblastoma (2019) (0)
- Biology of CAR-T Cells (2022) (0)
- Viewing T Cell Biology Through a Genomic Lens (2014) (0)
- High antigen density of BCMA: friend or foe to CAR T cells? (2022) (0)
- Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells (2023) (0)
- Limiting antigen escape in multiple myeloma by dual antigen-targeting of BCMA and TACI using the natural ligand APRIL (2017) (0)
- Blocking IFNγ in CAR-T Reduces Checkpoint Inhibitors and Cell-Mediated Toxicity without Compromising Therapeutic Efficacy in CD19 +malignancies (2021) (0)
- Abstract B05: A biologic screen to evaluate potential toxicity of chimeric antigen receptor modified T cells against primary normal human tissues (2015) (0)
- Overcoming a Critical Obstacle Towards Effective and Safe CAR T-Cell Therapeutics (2018) (0)
- Safety of genetically modified T cells. (2022) (0)
- Abstract 556: Novel anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma (2022) (0)
- Long Term Follow Up of the CAR T Recipient (2021) (0)
- Improving Therapy of Chronic Lymphocytic Leukemia (CLL) with Chimeric Antigen Receptor (CAR) T Cells (2016) (0)
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity (2019) (0)
- 4-1BB is Superior to CD28 Costimulation for Generating Effector CD8+ T Cells for Adoptive Immunotherapy (48.12) (2007) (0)
- 463 Tandem CAR T Cells Targeting EGFRvIII and IL-13R⍺2 are Effective Against Heterogeneous Glioblastoma (2023) (0)
- Abstract 3575: Differential dynamics of response at single cell resolution between axi-cel and tisa-cel CAR-T therapy in refractory B-cell lymphomas (2022) (0)
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma (2015) (0)
- Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma (2022) (0)
- False-positive HIV testing in patients receiving lentivirus-based chimeric antigen receptor T-cell therapy: A case report, review of the literature and proposed recommendations. (2021) (0)
- University of Southern Denmark Rational design of a trimeric April-based CAR-binding domain enables efficient targeting of multiple myeloma Schmidts, (2019) (0)
- CAR-T Cell Therapies for Non-Hematopoietic Malignancies: Taking Off The Training Wheels (2020) (0)
- Biomanufacturing for clinically advanced cell therapies (2018) (0)
- HIV-infected macrophages evade NK cell-mediated killing while driving inflammation (2019) (0)
- Hybrid CARs for Cancer? (2014) (0)
- Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas (2022) (0)
- Targeting CD79b with chimeric antigen receptors shows potent pre-clinical efficacy in mantle cell lymphoma (2019) (0)
- 10th Chabner Colloquium: Answering the Big Questions in Cancer Research (2019) (0)
- The Chicken or the Egg? Checkpoint Markers Identify Tumor-Specific T Cells in Melanoma (2014) (0)
- Versatile Polymer-Based Nanocarriers for Targeted Therapy and Immunomodulation (2021) (0)
- Publisher Correction: Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing (2020) (0)
- Dominant-Negative TGF- b Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication a phase I clinical trial to assess these CAR T cells as a novel approach for patients with relapsed and refractory metastatic prostate cancer (2018) (0)
- T Cells Through the Age(s) (2014) (0)
- 301 Single-cell RNA study of transcriptional activities associated with anakinra prophylaxis and axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma (2022) (0)
- Abstract 4098: Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics (2023) (0)
- Treatment of cancer using humanized chimeric anti-CD19 antigen receptor (2014) (0)
- CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells (2021) (0)
- CAR T Cells Advance to the Next Level (2014) (0)
- Chabner Colloquium: Answering the Big Questions in Cancer Research & 2016 STO Annual Meeting (Boston, MA: November 11-12, 2016) (2016) (0)
- The ultimate combination immunotherapy (2015) (0)
- 517. Improving CAR T Cell Efficacy for Solid Tumors By Nanogel-Based Delivery of Immunomodulatory Proteins (2015) (0)
This paper list is powered by the following services:
Other Resources About Marcela Maus
What Schools Are Affiliated With Marcela Maus?
Marcela Maus is affiliated with the following schools:
